Public Employees Retirement Association of Colorado Sells 949 Shares of Doximity, Inc. (NASDAQ:DOCS)

Public Employees Retirement Association of Colorado trimmed its stake in Doximity, Inc. (NASDAQ:DOCSFree Report) by 7.2% during the 2nd quarter, HoldingsChannel reports. The fund owned 12,228 shares of the company’s stock after selling 949 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Doximity were worth $342,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. LRI Investments LLC bought a new position in Doximity in the 1st quarter worth about $27,000. Blue Trust Inc. lifted its stake in shares of Doximity by 621.4% in the second quarter. Blue Trust Inc. now owns 1,385 shares of the company’s stock worth $37,000 after buying an additional 1,193 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Doximity during the first quarter valued at approximately $46,000. First Horizon Advisors Inc. increased its position in shares of Doximity by 80.0% during the second quarter. First Horizon Advisors Inc. now owns 1,710 shares of the company’s stock valued at $48,000 after acquiring an additional 760 shares in the last quarter. Finally, Van ECK Associates Corp raised its holdings in Doximity by 19.7% in the 2nd quarter. Van ECK Associates Corp now owns 2,590 shares of the company’s stock worth $72,000 after acquiring an additional 427 shares during the last quarter. 87.19% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DOCS has been the subject of several research analyst reports. Robert W. Baird lifted their price objective on Doximity from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. Morgan Stanley increased their price objective on shares of Doximity from $25.00 to $26.00 and gave the company an “underweight” rating in a research report on Friday, August 9th. Canaccord Genuity Group lifted their target price on shares of Doximity from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, August 20th. JPMorgan Chase & Co. increased their price target on Doximity from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Monday, August 19th. Finally, Barclays lifted their price objective on Doximity from $31.00 to $35.00 and gave the stock an “equal weight” rating in a report on Friday, August 9th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $32.42.

Get Our Latest Stock Report on DOCS

Insider Buying and Selling

In other Doximity news, Director Watkin Phoebe L. Yang sold 1,011 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $25.54, for a total transaction of $25,820.94. Following the sale, the director now directly owns 11,258 shares of the company’s stock, valued at $287,529.32. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Doximity news, CFO Anna Bryson sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $35.00, for a total value of $1,050,000.00. Following the completion of the transaction, the chief financial officer now directly owns 309,627 shares in the company, valued at approximately $10,836,945. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Watkin Phoebe L. Yang sold 1,011 shares of Doximity stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $25.54, for a total transaction of $25,820.94. Following the sale, the director now owns 11,258 shares in the company, valued at approximately $287,529.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,951 shares of company stock valued at $1,271,018. Company insiders own 39.40% of the company’s stock.

Doximity Stock Up 0.9 %

NASDAQ DOCS opened at $42.90 on Friday. The stock’s 50-day moving average price is $34.82 and its 200-day moving average price is $29.57. The company has a market capitalization of $7.96 billion, a P/E ratio of 59.58, a price-to-earnings-growth ratio of 5.80 and a beta of 1.27. Doximity, Inc. has a 52 week low of $19.89 and a 52 week high of $43.56.

Doximity (NASDAQ:DOCSGet Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.06. The business had revenue of $126.68 million for the quarter, compared to the consensus estimate of $119.88 million. Doximity had a net margin of 32.53% and a return on equity of 19.26%. Research analysts anticipate that Doximity, Inc. will post 0.8 EPS for the current year.

Doximity Profile

(Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Recommended Stories

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NASDAQ:DOCSFree Report).

Institutional Ownership by Quarter for Doximity (NASDAQ:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.